| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2842
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2842
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2021-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47745477c0f1521919526a19712ec089
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2c54ee199c35608f9db66ff9a796a68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94e76d6070a1f5eea9c874f0840c91a0 |
| publicationDate |
2021-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2021200518-A1 |
| titleOfInvention |
Methods for diagnosing and treating inflammatory bowel disease |
| abstract |
Biomarkers predictive of responsiveness to integrin beta7 antagonists, including antinbeta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In naddition, methods of treating gastrointestinal inflammatory disorders such as inflammatory nbowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided nare methods of using such predictive biomarkers for the treatment of inflammatory bowel ndiseases including ulcerative colitis and Crohn's disease.n6/77 nRemission nGZMA nFOXM1 I __ nTNFSF15 nSLC8A3 nMLK7.AS1 nECHi ___ nCCL3 nVNN3 nINHBA nVNN2 nIL18RAP nKLRB1 nREM2 nTMIGD2 ____ nAlpha.EI nTMEM154 nCCL2 nKCNMA1 nM~a nLRRC4 nGZM.B ____ nPHF14 nHAMP nCPA2 nLM04 nMUCLi nHIF nTM4SF4 nFGF7 nBEST2 nDDO nCCL3L3 nCCDC90A nMX1 nUROS nTMEM200A nFAM125B nGPR15 _____ nSSTR2 nCPA3 nMT1 M nFGF9 nTIFAB i nCXCR6 nCCL4L1.2 nFASLG nPMCH n0.01 0.1 1 10b 100 nFIG. 5 Treatment Effect Difference n(interaction Term Estimate, 95% CI) |
| priorityDate |
2014-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |